Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

2005 • 11,108 citations

Cancer treatment and survivorship statistics, 2016

2016 • 5,899 citations

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult

2005 • 4,274 citations

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

2009 • 3,773 citations

Cancer treatment and survivorship statistics, 2012

2012 • 2,846 citations

Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

1979 • 2,308 citations

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

2001 • 1,774 citations

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

2009 • 1,327 citations

Cardiovascular Complications of Cancer Therapy

2009 • 1,172 citations

Anthracycline-Induced Cardiomyopathy

2010 • 1,028 citations

Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

2006 • 979 citations

Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy

1991 • 934 citations

Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

2004 • 865 citations

Cardiovascular Complications of Cancer Therapy

2004 • 811 citations

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

2012 • 782 citations

American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects

2007 • 760 citations

Anthracycline-Induced Cardiotoxicity

1996 • 754 citations

Cardiotoxicity of Chemotherapeutic Agents

2000 • 694 citations

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

2010 • 670 citations

Guidelines for the Evaluation and Management of Heart Failure

1995 • 662 citations

Doxorubicin, DNA torsion, and chromatin dynamics

2013 • 620 citations

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

2010 • 611 citations

Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery

2002 • 574 citations

Determinants of Prognosis in Survivors of Myocardial Infarction

1982 • 528 citations

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

2000 • 519 citations

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy

1987 • 501 citations

Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies

2005 • 451 citations

Anthracycline Cardiotoxicity: From Bench to Bedside

2008 • 443 citations

Cancer drugs and the heart: importance and management

2012 • 443 citations

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

2010 • 398 citations

Anthracycline associated cardiotoxicity in survivors of childhood cancer

2007 • 363 citations

Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patients

2002 • 332 citations

HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches

1999 • 329 citations

Epidemiology of anthracycline cardiotoxicity in children and adults.

1998 • 326 citations

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

2002 • 305 citations

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

2012 • 304 citations

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

2009 • 256 citations

HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES

2000 • 252 citations

Anthracycline-induced cardiotoxicity in children and young adults

1998 • 207 citations

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

2012 • 207 citations

Anthracycline-induced cardiomyopathy

2001 • 136 citations

Anthracycline-induced cardiomyopathy

2001 • 129 citations

Preclinical models of bone metastases

2001 • 59 citations

Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction <40% Versus ≥40% (from the HORIZONS-AMI Trial)

2012 • 56 citations

Monitoring of Anthracycline-Induced Cardiotoxicity

2007 • 46 citations

Prevention of anthracycline-induced cardiotoxicity in children: The evidence

2007 • 42 citations

Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score

2013 • 40 citations

Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients

2014 • 34 citations

Cited By (0)

No citing papers found in database